Kura Oncology, Inc.
KURA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $54 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $1 | $0 | $0 |
| Gross Profit | $54 | -$1 | $0 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $170 | $115 | $93 | $85 |
| G&A Expenses | $77 | $51 | $47 | $47 |
| SG&A Expenses | $77 | $51 | $47 | $47 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$1 | $0 | $0 |
| Operating Expenses | $247 | $165 | $140 | $131 |
| Operating Income | -$193 | -$166 | -$140 | -$131 |
| % Margin | -358.5% | – | – | – |
| Other Income/Exp. Net | $21 | $13 | $4 | $1 |
| Pre-Tax Income | -$172 | -$153 | -$136 | -$130 |
| Tax Expense | $2 | $0 | $0 | $0 |
| Net Income | -$174 | -$153 | -$136 | -$130 |
| % Margin | -322.9% | – | – | – |
| EPS | -2.02 | -2.08 | -2.03 | -1.97 |
| % Growth | 2.9% | -2.5% | -3% | – |
| EPS Diluted | -2.02 | -2.08 | -2.03 | -1.97 |
| Weighted Avg Shares Out | 86 | 73 | 67 | 66 |
| Weighted Avg Shares Out Dil | 86 | 73 | 67 | 66 |
| Supplemental Information | – | – | – | – |
| Interest Income | $23 | $15 | $4 | $1 |
| Interest Expense | $2 | $2 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$169 | -$150 | -$135 | -$129 |
| % Margin | -314.6% | – | – | – |